Skip to main content

Select Drug Profiles

Getting Back to Reality: The Election, the Fiscal Cliff, and the ACA

Joseph R. Antos, PhD

APPENDIX: Detailed Methods

Real-Time Continuous Glucose Monitoring Cost-Effective in Patients with Type 2 Diabetes

Multiple Sclerosis: Patient Characteristics and Cost Concerns

Charles Bankhead, Medical Writer

Original Research

Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study

Barbara Lennert, RN, BSN, MAOM, Wendy Bibeau, PhD, Eileen Farrelly, MPH, Patricia Sacco, MPH, RPh, Tessa Schoor, MD

Stakeholder Perspective

Parkinson’s Disease: A Complicated but Underappreciated and Undertreated Condition

by Gary M. Owens, MD

Practice Management

Cost Management through Care Management, Part 2: The Importance of Managing Specialty Drug Utilization in the Medical Benefit

Michael T. Einodshofer, RPh, MBA, Lars N. Duren, BCNSP, PharmD

Practice Management

Medical Care Costs and Hospitalization in Patients with Bipolar Disorder Treated with Atypical Antipsychotics

Joette Gdovin Bergeson, PhD, MPA, Iftekhar Kalsekar, PhD, Yonghua Jing, PhD, Min You, MS, Robert A. Forbes, PhD, Tony Hebden, PhD

Stakeholder Perspective

The Potential Value of Benefit Design and Medication Selection for a Total-Cost-of-Care Strategy in Bipolar Disease

by Jeff Januska, PharmD

Payer Drug and Molecular Testing Utilization Policies

Charles Bankhead, Medical Writer

Hardworking P&T Committees

David B. Nash, MD, MBA

Practice Management

"Hidden” Value: How Indirect Benefits of Health Information Exchange Further Promote Sustainability

Albert Tzeel, MD, MHSA, CPE, FAAPL, Victor Lawnicki, PhD, Kim R. Pemble, MS

Stakeholder Perspective

Significant Potential for Health Information Exchange in Enhancing Quality of Care and Reducing Hospital Admissions in the United States

by Jack E. Fincham, PhD, RPh

Page 190 of 244
Results 1891 - 1900 of 2434